Key highlights

  • SportsHero rose 15.63% to $0.037, Archer Materials rose 11.77% to $0.190 and Appen rose 11.54% to $1.160 at 11:04 AM AEDT on 19 November 2026.
  • Archer Materials completed a Beta prototype of its Biosensor blood-testing kit on 19 November 2026.
  • Appen reported Q3 FY26 Revenue of $73.9 million, up 34% on the prior corresponding period.

Three ASX technology companies gained in mid-morning trade on 19 November 2026, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. SportsHero Limited (ASX:SHO) traded at $0.037, up 15.63%. Archer Materials Limited (ASX:AXE) traded at $0.190, up 11.77%, and Appen Limited (ASX:APX) traded at $1.160, up 11.54%. The three companies span gaming, quantum and medical diagnostics technology, and AI Training data, and each has recent operating updates. The figures quoted are intraday prices at 11:04 AM AEDT on 19 November 2026, reflecting trade in progress at that time rather than closing prices. Each share price is shown as traded during the session, so later moves may differ from the figures quoted here. The S&P/ASX 200 figures are the level and percentage change quoted at midday on the same day.

SportsHero (ASX:SHO): HeroPlay Soft Launch Metrics

SportsHero reported on 10 November 2026 that its HeroPlay Gaming Universe ran a five-day soft launch timed to an Indonesian mobile game tournament. The platform recorded more than 80,000 site visits and 215,000 page views, and it performed without technical issues. A total of 9,322 users registered, a visit-to-registration conversion of 11.6%, and 3,728 registered users, about 40%, redeemed an in-game reward. The company recorded more than 600 purchase attempts at an average of about A$6.69. Integration of additional product categories from existing supplier partners is planned over the coming weeks.

SportsHero describes itself as an integrated digital gaming and esports Business focused on the South East Asia market. Management said all four key tests of the soft launch were validated, including whether gamers would move from free video channels to the platform, and it expects the results to help guide its strategy with telecommunications partners in the region.

Archer Materials (ASX:AXE): Biosensor Beta Prototype

Archer Materials announced on 19 November 2026 that its Biosensor beta prototype is complete. The integrated point-of-care kit combines a cartridge, chip packaging, sensors, a reader and readout electronics, and the company says it returns a result about six minutes after a fingerprick sample. The prototype is ready for external testing, and initial Manufacturing design is starting with specialist contract manufacturers. Lithium testing is the first application, with discussions under way with tier-one clinical partners in Australia and internationally to compare it with established laboratory methods.

The Biosensor is one part of a broader technology program that the company describes across quantum computing, sensing and medical diagnostics. Chief executive Dr Simon Ruffell has said the next phase is about building evidence on how the device performs in practical settings, using feedback from manufacturing and clinical partners to guide its final development.

Appen (ASX:APX): Q3 FY26 Revenue Growth

Appen reported on 29 October 2026 that revenue for the third quarter of FY26 was $73.9 million, up 34% on the prior corresponding period, with underlying EBITDA before currency effects of $10.3 million. Appen China revenue rose 61% to $46.1 million, with an annualised run-rate above $190 million in September. Appen Global returned to profit, with revenue of $27.9 million and underlying EBITDA of $5.6 million. The company maintained FY26 revenue guidance of $270 million to $300 million, with revenue currently expected in the lower half of that range.

Chief executive Ryan Kolln said the company now counts seven of the eight largest US-based AI model builders as customers, with a project in the pipeline with the eighth. Revenue outside the largest Appen Global client grew 70% on the prior quarter, and the quarter’s figures are unaudited management accounts that remain subject to audit.